Canaccord Genuity Group Lowers TriSalus Life Sciences (NASDAQ:TLSI) Price Target to $11.00

TriSalus Life Sciences (NASDAQ:TLSI) had its target price trimmed by Canaccord Genuity Group from $12.00 to $11.00 in a report released on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also recently commented on the company. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Northland Securities initiated coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 target price on the stock. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Roth Mkm assumed coverage on shares of TriSalus Life Sciences in a research report on Monday, November 11th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, Oppenheimer assumed coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 target price for the company. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, TriSalus Life Sciences currently has a consensus rating of “Buy” and an average target price of $12.08.

TriSalus Life Sciences Price Performance

NASDAQ:TLSI opened at $3.67 on Friday. The firm has a market capitalization of $111.90 million, a price-to-earnings ratio of -1.47 and a beta of 0.49. TriSalus Life Sciences has a one year low of $3.32 and a one year high of $10.42. The business has a fifty day moving average price of $4.30 and a 200-day moving average price of $5.71.

Insider Activity

In related news, CEO Mary T. Szela bought 7,520 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were purchased at an average price of $5.20 per share, with a total value of $39,104.00. Following the transaction, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. This trade represents a 2.03 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Several large investors have recently modified their holdings of TLSI. Geode Capital Management LLC grew its position in TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares during the last quarter. Vestcor Inc purchased a new stake in TriSalus Life Sciences in the third quarter valued at about $108,000. MSD Partners L.P. purchased a new stake in TriSalus Life Sciences in the third quarter valued at about $184,000. Walleye Capital LLC purchased a new stake in TriSalus Life Sciences in the third quarter valued at about $66,000. Finally, Duquesne Family Office LLC raised its stake in TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the last quarter. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.